PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2116564
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2116564
According to Mordor Intelligence, the global suture anchor devices market size was valued at USD 860 million in 2025 and estimated to grow from USD 906.1 million in 2026 to reach USD 1,176.74 million by 2031, at a CAGR of 5.36% during the forecast period (2026-2031).

This report is Segmented by Product Types (Absorbable and Non-Absorbable), Material Type (Metal, Bio-Absorbable Polymer, and More), Fixation Mechanism (Knotted, Knotless, and Tape-Based), Application (Shoulder-Rotator Cuff, Hip-labral & FAIS, and More), End-User (Hospitals, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
An expanding cohort of adults over 65 now drives roughly half of the 18.5 million orthopedic procedures performed annually in the United States. Higher life expectancy and active lifestyles mean more patients present with rotator-cuff tears, osteoarthritis, and hip fractures, all of which routinely require anchor fixation. Germany anticipates knee arthroplasty incidence to climb 55% by 2040, illustrating demographic pull across Europe. In parallel, U.S. outpatient reimbursement uplifts make anchor-based repairs viable in non-acute settings, reinforcing volume growth. These intersecting trends underpin durable demand for the suture anchor devices market.
Nano-arthroscopy has reduced portal size to 2 mm, enabling procedures under local anesthesia that bypass full-scale operating rooms. Arthrex's NanoScope platform exemplifies this shift with single-use 1 mm imaging sensors that also serve as MRI alternatives. Clinical data show needle arthroscopy produces lower post-op pain scores compared with standard techniques, while ASCs can perform such cases at 26% lower cost than hospital outpatient departments. As minimally invasive preferences deepen, procedure counts-and by extension the suture anchor devices market-are set to rise.
Polyglycolic acid anchors evoke granulomatous inflammation requiring surgical drainage in 6.3% of cases, with hospital stays averaging 18 days. Osteolytic tunnels can appear 12 weeks post-op, compromising fixation integrity. Carbon-fiber PEEK plates also shed particles that elevate local cytokine response. These biocompatibility hurdles temper near-term uptake of newer materials in the suture anchor devices market.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Absorbable anchors represent the innovation vanguard. In 2025 non-absorbables retained the largest block at 53.02% revenue, yet absorbables are projected to outpace with an 8.13% CAGR. This divergence directly increases the suture anchor devices market size captured by degradable formats as hospitals shift to MRI-friendly post-op protocols. Smith & Nephew's REGENESORB platform, which converts to bone within two years, embodies the clinical argument for resorption. Surgeons remain cautious because 4.3% of bio-polymer cases show adverse reactions, but ongoing polymer science is trimming complication rates. Government standards like ASTM F2579-18 certify performance criteria, easing tender participation and reinforcing confidence in the suture anchor devices market.
The non-absorbable category still commands surgeon loyalty where high-load bearing and long-term certainty are paramount. Metallic anchors excel in revision scenarios, while expanded PEEK lines deliver bone-like modulus to mitigate stress shielding. As competitive suppliers blend absorbable tips with non-absorbable cores, hybrid designs will blur categorical lines, sustaining wide choice within the suture anchor devices market.
PEEK and carbon-reinforced PEEK formed 35.12% of overall revenue in 2025, giving this high-performance polymer the single-largest material footprint in the suture anchor devices market share. Machinability and CT-compatibility make PEEK a default in complex shoulder and hip work. Evonik's VESTAKEEP i4 3DF now enables ASTM F2026-compliant 3-D printed implants, unlocking surgeon-specific geometries. Yet bio-polymers such as PLLA and PLGA are accelerating at 8.03% CAGR, underpinned by degradability and osteoconductive fillers.
Titanium and stainless steel retain niches in trauma and hard-bone fixation where permanent strength overrides imaging concerns. Coralline graft composites and biphasic calcium phosphate-doped PEEK offer middle-ground solutions that encourage bone in-growth. Over the forecast period, material diversity is likely to intensify as suppliers hedge against PEEK supply concentration, cushioning the suture anchor devices market against raw-material shocks.
North America generated 40.33% of 2025 revenue and remains the technology bellwether for the suture anchor devices market. Medicare's 36.2% rise in outpatient shoulder arthroplasty reimbursement, together with a 2.9% facility-wide uplift, reinforces hospital and ASC economics. Canadian universal coverage ensures consistent baseline volumes, while Mexican medical-tourism corridors broaden the regional patient pool.
Europe contributes stable but slower growth as national health systems impose strict cost containment. Medical Device Regulation (EU) 2017/745 compels recertification of legacy anchors, adding compliance costs yet heightening product quality. Germany's knee and hip replacement projections underpin procedure demand, whereas microplastics rules effective October 2029 will steer material choices toward eco-compliant polymers.
Asia-Pacific is on a 9.14% CAGR trajectory, outpacing all regions. Japan showcases early adoption of robotic arthroplasty and absorbable anchors to manage an aging demographic. India and ASEAN nations prioritize capacity investments; reference-market inclusion changes in Australia simplify device approvals, speeding cross-border introduction. Manufacturers with regional assembly or price-band portfolios will capture outsized upside in this high-growth theater of the suture anchor devices market.